Thromboembolism in multiple myeloma patients receiving thalidomide combination chemotherapy.

被引：0
|
作者：
Wrigh, A. [1 ]
Elkins, S. [1 ]
Files, J. [1 ]
Bigelow, C. [1 ]
Herrin, V. [1 ]
Sample, M. [1 ]
机构：
[1] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2007年 / 55卷 / 01期
关键词：
D O I：
10.1097/00042871-200701010-00839
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S302 / S302
页数：1
相关论文
共 50 条
  • [41] COMBINATION CHEMOTHERAPY IN MULTIPLE-MYELOMA
    DURIE, BGM
    CANCER INVESTIGATION, 1986, 4 (05) : 487 - 487
  • [42] COMBINATION CHEMOTHERAPY FOR MULTIPLE-MYELOMA
    SALMON, SE
    DURIE, BGM
    ALEXANIAN, R
    BLOOD, 1975, 46 (06) : 1039 - 1039
  • [43] Thalidomide plus CED-chemotherapy in patients with poor prognosis multiple myeloma.
    Moehler, TM
    Neben, K
    Egerer, G
    Punzel, M
    Schmier, J
    Cremer, F
    Goldschmidt, H
    Ho, AD
    BLOOD, 1999, 94 (10) : 124A - 125A
  • [44] Thalidomide as anti-angiogenesis treatment in patients with chemotherapy resistant multiple myeloma (MM).
    Wu, K
    Schaafsma, MR
    Smit, WM
    Neef, C
    Richel, DJ
    BLOOD, 1999, 94 (10) : 316B - 316B
  • [45] Efficacy and tolerability of combination thalidomide-dexamethasone in multiple myeloma patients with refractory disease
    Hatjiharissi, E
    Gerotziafas, G
    Papaioannou, M
    Bakaloudi, V
    Tokmaktsis, A
    Kaloutsi, V
    Christakis, J
    Zervas, K
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 104 - 104
  • [46] Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma
    Schütt, P
    Ebeling, P
    Buttkereit, U
    Brandhorst, D
    Opalka, B
    Hoiczyk, M
    Flasshove, M
    Hense, J
    Bojko, P
    Metz, K
    Moritz, T
    Seeber, S
    Nowrousian, MR
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 74 (01) : 40 - 46
  • [47] Evaluation of the Relationship Between Venous Thromboembolism Risk Factors and the Use of Antithrombotic Prophylaxis in Multiple Myeloma Patients Treated with Thalidomide and Dexamethasone Combination Regimens
    Brandenburg, Nancy A.
    Goss, Thomas F.
    Knight, Tyler
    Xu, Xiao
    Knight, Robert D.
    BLOOD, 2008, 112 (11) : 825 - 826
  • [48] Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide
    Mileshkin, L
    Prince, HM
    Seymour, JF
    Biagi, JJ
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (04) : 747 - 748
  • [49] Incidence and clinical course of peripheral neuropathy in patients receiving thalidomide for the treatment of multiple myeloma.
    Naina, HVK
    Lacy, MQ
    Dispenzieri, A
    Kumar, S
    Greipp, PR
    Witzig, TE
    Gertz, MA
    Rajkumar, SV
    BLOOD, 2005, 106 (11) : 970A - 970A
  • [50] Survival outcomes of patients receiving thalidomide-dexamethasone for previously untreated multiple myeloma.
    Thomas, Sheeba K.
    Giralt, Sergio A.
    Wang, Michael
    Delasalle, Kay B.
    Gavino, Maria
    Rankin, Kim
    Alexanian, Raymond
    Weber, Donna M.
    BLOOD, 2006, 108 (11) : 1019A - 1019A
12345